Exclusion Criteria:~* Failure to perform screening or baseline examinations~* Hospitalization or change of
concomitant medication 1 month prior to Screening visit or during Screening Period~* Clinical, laboratory or
neuroimaging findings consistent with:~ 1. Other primary degenerative dementia;~ 2. Other neurodegenerative
condition;~ 3. Cerebrovascular disease;~ 4. Other central nervous system diseases;~* A current Diagnostic and
Statistical Manual-5 (DSM-5) diagnosis of major depression, schizophrenia or bipolar disorder~* Positive
results for tuberculosis, human immunodeficiency virus (HIV), hepatitis C or hepatitis B (hepatitis B surface
antigen \[HbsAg\]) serology at the Screening Visit~* Clinically significant, advanced or unstable disease that
may interfere with evaluation.~* Disability that may prevent the patients from completing all study
requirements.~* Chronic drug intake of forbidden concomitant medication.~* Treatment with anti-amyloid beta or
anti-Tau protein monoclonal antibodies or other disease modifying strategies within three months or five
half-lives, whichever is longer, prior to the Screening Visit~* Treatment with an active vaccine targeting
amyloid beta or Tau protein~* Suspected or known drug or alcohol abuse~* Metallic implants or any other cause
precluding the performance of brain MRI~* Enrolment in another investigational study or intake of
investigational drug within the previous 3 months since the last dose~* Suicide attempt within the last year or
significant risk of suicide (in the opinion of the investigator, defined as a yes to suicidal ideation
questions 4 or 5, or answering yes to suicidal behavior on the Columbia-Suicide Severity Rating Scale within
the past 12 months)~* Any condition that in the opinion of the investigator makes the patient unsuitable for
inclusion in the study
